Kymera Therapeutics Inc [KYMR] stock prices are up 8.46% to $42.30 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The KYMR shares have gain 39.83% over the last week, with a monthly amount glided 22.36%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Kymera Therapeutics Inc [NASDAQ: KYMR] stock has seen the most recent analyst activity on April 22, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $53. On January 04, 2024, upgrade upgraded it’s rating to Overweight. BofA Securities downgraded its rating to a Neutral and decreased its price target to $30 on January 03, 2024. Wells Fargo downgraded its rating to a Equal Weight but $26 remained the price target by the analyst firm on December 19, 2023. Truist started tracking with a Buy rating for this stock on June 30, 2023, and assigned it a price target of $50. In a note dated May 05, 2023, Raymond James upgraded an Outperform rating on this stock.
The stock price of Kymera Therapeutics Inc [KYMR] has been fluctuating between $9.60 and $45.31 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Kymera Therapeutics Inc [NASDAQ: KYMR] shares were valued at $42.30 at the most recent close of the market. An investor can expect a potential return of 13.48% based on the average KYMR price forecast.
Analyzing the KYMR fundamentals
The Kymera Therapeutics Inc [NASDAQ:KYMR] reported sales of 79.41M for trailing twelve months, representing a surge of 8.67%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -2.18%, Pretax Profit Margin comes in at -1.95%, and Net Profit Margin reading is -1.95%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.32 and Total Capital is -0.21. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 40.09 points at the first support level, and at 37.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 43.62, and for the 2nd resistance point, it is at 44.93.
Ratios To Look Out For
It’s worth pointing out that Kymera Therapeutics Inc [NASDAQ:KYMR]’s Current Ratio is 9.57. In addition, the Quick Ratio stands at 9.57 and the Cash Ratio stands at 1.67. Considering the valuation of this stock, the price to sales ratio is 32.69, the price to book ratio is 3.65.
Transactions by insiders
Recent insider trading involved Booth Bruce, Director, that happened on Jul 09 ’24 when 0.45 million shares were sold. Director, Booth Bruce completed a deal on Jun 13 ’24 to sell 10200.0 shares. Meanwhile, Director Booth Bruce sold 16740.0 shares on Jun 12 ’24.
